In the era of targeting therapy for lung cancer, EGFR-TKI have been proven as the pivotal therapeutic role for NSCLC harboring an active EGFR mutation in terms of response rate, PFS and OS [5,6,7]. This evidence concerns the gene EGFR and lung cancer.